Results for tag: "Erivedge"

Erivedge is a drug used to treat advanced basal cell carcinoma (BCC), a type of skin cancer. It is the first and only FDA-approved medicine for this indication. Erivedge works by blocking the activity of a protein called Hedgehog, which is involved in the growth and spread of BCC. The drug is administered orally, and is available in capsule form. Erivedge is marketed by Genentech, a subsidiary of Roche, and is available in the United States, Canada, and Europe. It is also approved for use in Australia, New Zealand, and several other countries. The Erivedge market is highly competitive, with several other drugs available for the treatment of advanced BCC. These include vismodegib, sonidegib, and imiquimod. In addition, there are several other drugs in development for the treatment of BCC, including talimogene laherparepvec and avelumab. The Erivedge market is also characterized by a high degree of innovation, with new drugs and treatments being developed to improve outcomes for patients with advanced BCC. Companies in the Erivedge market include Genentech, Roche, Pfizer, Novartis, Merck, and GlaxoSmithKline. Show Less Read more